ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY

Corporate Breaking News

Home : ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY

Dec 14 2021	ICHNOS SCIENCES AND ALMIRALL ENTER INTO A LICENSING AGREEMENT FOR FIRST-IN-CLASS IL-1RAP ANTAGONIST MONOCLONAL ANTIBODY
NEW YORK and BARCELONA, Spain, Dec. 14, 2021 /PRNewswire/ -- Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announced today...


Source:https://www.prnewswire.com:443/news-releases/ichnos-sciences-and-almirall-enter-into-a-licensing-agreement-for-first-in-class-il-1rap-antagonist-monoclonal-antibody-301443735.html

Related News
» Pioneering New EVs Lead Hyundai Motor Group's Record Number of Global Awards in 2021 » Indonesia lifts tsunami alert after powerful undersea quake